





## A Microcidal Drain Tube Attachment

Student Designers: Kelsey Hoegh, Tanner Marshall, Laura Platner, Taylor Powers, Daniel Tighe. Advisor: Professor Mitch Tyler. Client: Dr. Samuel Poore

## Motivation

- Post-surgical drain tube required for mastectomy patients with expander for reconstruction [1]
- 114,000 mastectomies/year performed in United [4]




Figure 1. Close up view of a fluted drain tube with exploded cross-section <a href="http://www.ctsnet.org/peterssurgical">http://www.ctsnet.org/peterssurgical</a>

- 12 26% of these patients develop surgical site infections (SSI) [5]
- 5% require second operation due to SSI [1]
- Expensive end effect: \$757 million spent/year to treat [6]
- More negative effects: longer recovery, more complications
- The drain-tube related SSI problem extends beyond mastectomy patients




Figure 2. Diagram of a surgical drain tube. <a href="http://www.cancer.sutterhealth.orginformation/">http://www.cancer.sutterhealth.orginformation/</a> bc\_notebook/postoperative\_care.html>

## **Current Technologies**

#### The Competition

#### **Biopatch®**

- Releases CHG up to 7 days [2]
- Tailored for catheters, not drain tubes
- Lacks attachment mechanism

#### **Elutia**®

Tested for 7 days

**Tested Inhibition** 

- Silicone drain tube
- Silver hydrogel coating [4]




Figure 3. Diagram of a Biopatch® used on skin with a catheter. <a href="http://www.ethicon360.com/products/biopa">http://www.ethicon360.com/products/biopa</a> tch-protectivedisk-chg>

**Quantitative Analysis** 

#### **Design Criteria for Improved** Solution

- Operate *in vivo* for 2 weeks
- Easy interface to currently available surgical drains
- Reduce wound dressing
- Biocompatible
- Easily manufactured

## **Proposed Solution**

# 

## Figure 4: Bottom view of CidalSeal

#### **Suture Tab**

- Facilitates Attachment of CidalSeal™ to Skin
- Ovoid Shape for Mechanical Strength

than CHG

### **Chlorhexidine Gluconate Impregnated Foam Disc**

8

- Primary Antibacterial Agent
- 3% CHG Solution

Figure 5: Top Isometric view diagram of the CidalSeal

#### **Silicone Extension**

- Facilitates Attachment of CidalSeal™ to Drain Tube
- Provides Extra Friction Forces to Prevent Slipping

#### against 4 **Inhibition Zone Diameter** bacterial species Foam Diameter Figure 7: An example showing the method of measurement for inhibition **Bacterial Growth**


#### 14 days of bacterial infection protection


- Competing products only last 7 days
- Protection of 4 common infections


#### **Protection against Pseudomonas aeruginosa**

- Failure after 6 days with CHG foam
- Biopatch only microcidal agent is CHG
- Full 14 days protection with Silver sulfadiazine foam

#### Improvement of attachment/removal process







- Only 2 sutures needed for attachment
- Reducing dressings/tape decreases pain for patient upon removal

# Cost Analysis

Protects Against Different Bacterial Infections

Silver Sulfadiazine Impregnated Foam Band

Secondary Microcidal Agent

#### **Clinical impact:**

#### • \$757 million spent per year to treat SSI's from mastectomy patients alone [6]

 Drain tubes also used in plastic, orthopedic, and other cardiothoracic surgeries

#### **Manufacturing Costs:**

 An initial tooling cost estimated at \$1445.00

Product	Price Per Unit
Biopatch®	\$11.30
CidalSeal™	\$1.90

## Moving Forward

**Testing:** In vitro testing

#### **Manufacturing:**

Figure 6: Bottom Isometric view diagram of the

- Scale up from in lab to industry
- Possibility of injection molding for silicone
- Improve pressure clip

## **Companies of interest:**

#### Johnson & Johnson

- Cardinal Health
- Jackson Pratt drain
- BARD Medical
- Plus others

## References

#### References

[1] "Postoperative Care; Wound Dressing and Drain Care." Cancer Services at Sutter Health. Web. 07 Mar. 2011. <a href="http://www.cancer.sutterhealth.org/information/bc/notebook/postoperative\_care.html">http://www.cancer.sutterhealth.org/information/bc/notebook/postoperative\_care.html</a>.

[2] BioPatch: Protective disk with CHG. Ethicon 360. [online] Referenced Feb 27, 2011.

<a href="http://www/ethicon360.com/products/biopatch-protective-disk-chg">http://www/ethicon360.com/products/biopatch-protective-disk-chg</a>. [3] <a href="http://www.ctsnet.org/peterssurgicalTestingFinal">http://www.ctsnet.org/peterssurgicalTestingFinal</a>

Surg. September 2008; 207 (3): 326-335

[4] Habermann, E., B., Abbott, A., Parsons, H., M., Virnig, B., A., Al-Refaie, W., B., Tuttle, T., M. (2010). Are Mastectomy Rates Really Increasing in the United States? Journal of Clinical Oncology. 28, 3437-3441. [5] Olsen MA, Lefta M, Dietz JR, et al. Risk factors for surgical site infection after major breast operation. J Am Coll

[6] Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am. J. Infec. Control. 2005;33(9):501-509. 3 ICT

#### Acknowledgements

Dr. John Puccinelli; UW Madison Biomedical Engineering, Dr. Andrew Navarrete